09/ 755,021

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:36:44 ON 05 MAY 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:37:22 ON 05 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 MAY 2005 HIGHEST RN 849790-35-8
DICTIONARY FILE UPDATES: 4 MAY 2005 HIGHEST RN 849790-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\09755021.str



chain nodes :
13 14 15 19 20 23 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-7 7-19 10-13 13-14 14-15 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
10-13 14-15 19-20
exact bonds :
1-7 7-8 7-12 7-19 8-9 9-10 10-11 11-12 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 :

G1:O,S,N

G2:Ph,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 19:CLASS 20:CLASS 23:CLASS
24:CLASS 25:Atom
Element Count :
Node 25: Limited
C,C5
N,N1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample
SAMPLE SEARCH INITIATED 16:37:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3012 TO ITERATE

33.2% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 56949 TO 63531
PROJECTED ANSWERS: 1 TO 164

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:37:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 61895 TO ITERATE

100.0% PROCESSED 61895 ITERATIONS 40 ANSWERS
SEARCH TIME: 00.00.02

L3 40 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 16:38:02 ON 05 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 May 2005 VOL 142 ISS 19
FILE LAST UPDATED: 4 May 2005 (20050504/ED)

09/ 755,021

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l3
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L3 ANSWER 1 OF 40 REGISTRY COPYRIGHT 2005 ACS on STN
RN 771463-77-5 REGISTRY
ED Entered STN: 28 Oct 2004
CN 4-Morpholinecarboxamide, N-[3-[4-(5-fluoro-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-3-oxo-5-phenyl-, (-)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H36 F N3 O4
CI COM
SR CA

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

09/ 755,021

```
=> d l1
L1 HAS NO ANSWERS
L1                STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l3
L4            12 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):y
```

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:645688 CAPLUS
DOCUMENT NUMBER: 140:138709
TITLE: Self-organizing molecular field analysis on α1a-adrenoceptor dihydropyridine antagonists
AUTHOR(S): Li, Minyong; Du, Lupei; Wu, Bin; Xia, Lin
CORPORATE SOURCE: Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, Peop. Rep. China
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(18), 3945-3951
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Self-organizing mol. field anal. (SOMFA), a new three-dimensional quant. structure-activity relationship (3-D-QSAR) method is used to study the correlation between the mol. properties and the α1a-AR biol. activities of dihydropyridine derivs. The statistical result, cross-validated q2 (0.690) and non cross-validated r2 (0.704) values, show a good predictive ability.

IT **166808-19-1**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(self-organizing mol. field anal. on α1a-adrenoceptor dihydropyridine antagonists)

RN 166808-19-1 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-N3-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-6-methyl-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:560064 CAPLUS
DOCUMENT NUMBER: 135:137519
TITLE: Preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α1c antagonists
INVENTOR(S): Nagarathnam, Dhanapalan; Chiu, George; Dhar, T. G. Murali; Wong, Wai C.; Marzabadi, Mohammad R.; Gluchowski, Charles; Lagu, Bharat; Miao, Shou Wu
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corp., USA
SOURCE: U.S., 67 pp., Cont.-in-part of U. S. Ser. No. 340,611, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6268369	B1	20010731	US 1997-836628	19970516
WO 9614846	A1	19960523	WO 1995-US15025	19951116
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6248747	B1	20010619	US 1999-291553	19990414
US 6727257	B1	20040427	US 2000-730458	20001205
PRIORITY APPLN. INFO.:			US 1994-340611	B2 19941116
			WO 1995-US15025	W 19951116
			US 1997-836628	A1 19970516
			US 1997-978682	A3 19971126

OTHER SOURCE(S): MARPAT 135:137519
GI

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB Title compds. [e.g., I; R = (un)substituted (hetero)aryl; R1 = H, (fluoro)alkyl, cyano, CO2R3, etc.; R2 = H, alkyl, OR3, etc.; R3 = H, (fluoro)alkyl, etc.; R4 = e.g, (4-arylpiperidinopropyl)carbamoyl; X = O, S, (alkyl)imino] and analogs thereof were prepared Over 60 synthetic examples were provided. Thus 1,6-dihydro-5-(cyanoethoxycarbonyl)-4-ethyl-6-(4-nitrophenyl)-2-methoxypyrimidine (prepared in 3 steps) was treated with 4-nitrophenylchloroformate (acylation at N1) followed by the corresponding substituted piperidine to give the N1 carboxamide intermediate. The cyanoethoxycarbonyl function was saponified and converted to the 5-carboxamido derivative II. Thus, title compound II had pKi of 9.74 for binding at human α1c receptors in vitro. Treatment of benign prostatic hyperplasia is a claimed use of the invention.

IT **179480-91-2P 179480-95-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α1c antagonists)

RN 179480-91-2 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-1-[[[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-6-(4-nitrophenyl)-2-thioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 179480-95-6 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-1-[[[3-[4-(4-

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT **166809-56-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α1c antagonists)

RN 166809-56-9 CAPLUS
CN 1-Piperidinepropanamine, 4-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:874202 CAPLUS
DOCUMENT NUMBER: 134:29410
TITLE: Preparation of oxazolidinones and related compounds as adrenergic α1A receptor antagonists
INVENTOR(S): Lagu, Bharat; Dhar, Tg Murali; Nagarathnam, Dhanapalan; Jeon, Yoon T.; Marzabadi, Mohammad R.; Wong, Wai C.; Gluchowski, Charles
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA
SOURCE: U.S., 74 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6159990	A	20001212	US 1998-99225		19980617
US 6620815	B1	20030916	US 2000-636518		20000810
PRIORITY APPLN. INFO.:			US 1997-50096P	P	19970618
			US 1998-99225	A1	19980617

OTHER SOURCE(S): MARPAT 134:29410
GI



I

AB Title compds. [I; X = O, S; X1 = O, S, NH; R2 = H, (CH2)rXR3, CO2R3, alkyl, aminoalkyl, alkenyl, alkynyl, etc.; r = 1-4; R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; R4 = (substituted) aryl, heteroaryl, aralkyl, heteroarylalkyl, etc.; R5 = H, (substituted) aryl, aralkyl, heteroarylalkyl, heteroaryl; adjacent R2R5 = aryl, heteroaryl, indanyl, tetrahydronaphthyl, cycloalkyl, heterocyclyl; Z = (substituted) acyl, alkenyl linker; R1 = (substituted) arylpiperidinyl, arylpiperazinyl, etc.], were prepared Thus, 4-(3,4-difluorophenyl)oxazolidin-2-one was stirred with NaH in THF/HMPA followed by addition of 1,5-dibromopentane to give 50% 4-(3,4-difluorophenyl)-1-(5-bromopentyl)oxazolidin-2-one. this was refluxed with K2CO3 and 1-(2-methoxyphenyl)piperazine in dioxane to give 88% 4-(3,4-difluorophenyl)-3-[5-[4-(2-methoxyphenyl)piperazin-1-yl]pentyl]oxazolidin-2-one. The latter bound to human α1A, α1D α1B receptors with Ki = 0.5, 11, and 21, resp.

IT **218449-46-8P 218449-47-9P 218451-05-9P 218451-09-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinones and related compds. as adrenergic α1A receptor antagonists)

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 218451-09-3 CAPLUS
CN 1-Imidazolidinecarboxamide, 5-(3,4-difluorophenyl)-N-[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



IT **216311-08-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolidinones and related compds. as adrenergic α1A receptor antagonists)
RN 216311-08-9 CAPLUS
CN 1-Piperidinepropanamine, 4-(2-methoxy-5-methylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 218449-46-8 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[3-[4-(5-bromo-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-4-(3,4-difluorophenyl)-2-oxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 218449-47-9 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[3-[4-(5-bromo-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-4-(3,4-difluorophenyl)-2-oxo-, monohydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 218451-05-9 CAPLUS
CN 1-Imidazolidinecarboxamide, 5-(3,4-difluorophenyl)-N-[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **218449-44-6P 218449-45-7P 218451-03-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidinones and related compds. as adrenergic α1A receptor antagonists)
RN 218449-44-6 CAPLUS
CN Carbamic acid, [3-[4-(5-bromo-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 218449-45-7 CAPLUS
CN 1-Piperidinepropanamine, 4-(5-bromo-2-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 218451-03-7 CAPLUS
CN 1-Imidazolidinecarboxamide, 5-(3,4-difluorophenyl)-N-[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]-2-oxo-3-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:421119 CAPLUS
DOCUMENT NUMBER: 133:58807
TITLE: Preparation of morpholine derivatives as selective antagonists of α1a receptors.
INVENTOR(S): Lagu, Bharat; Nagarathnam, Dhanapalan; Tian, Dake; Gluchowski, Charles
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035891	A1	20000622	WO 1999-US30259	19991217
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6218390	B1	20010417	US 1998-213539	19981217
CA 2355201	AA	20000622	CA 1999-2355201	19991217
EP 1140876	A1	20011010	EP 1999-966439	19991217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002532480	T2	20021002	JP 2000-588152	19991217
AU 770520	B2	20040226	AU 2000-21973	19991217
US 6362182	B1	20020326	US 2000-702015	20001030
US 2002068737	A1	20020606	US 2001-17263	20011214
US 6531471	B2	20030311		
US 2003212062	A1	20031113	US 2003-386083	20030311

PRIORITY APPLN. INFO.: US 1998-213539 A 19981217
WO 1999-US30259 W 19991217
US 2000-702015 A1 20001030
US 2001-17263 A1 20011214

OTHER SOURCE(S): MARPAT 133:58807
GI



AB Title compds. [I; II; III; W = O, S, NR8; R8 = H, alkyl, alkenyl, alkynyl,

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
cycloalkyl, cycloalkenyl; Y = O, S; R1 = specified (substituted) piperidinylalkylaminocarbonyl, piperazinylalkylaminocarbonyl, etc.; R2 = (substituted) aryl, heteroaryl; R3 = H, alkyl, fluoroalkyl, polyfluoroalkyl; R4-R7 = H, (CH2)tYR8, (CH2)tCO2R8, (CH2)tCN, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) Ph, PhCH2, etc.; Q = (CH2)0-4; Y = O, S], were prepd. Thus, (+)-3-(3,4-difluorophenyl)-5-oxomorpholine-4-carboxylic acid 4-nitrophenyl ester (prepn. given) and 3-[4-(5-fluoro-2-methoxyphenyl)-4-phenylpiperidin-1-yl]propylamine were stirred at room temp. overnight in THF to give (+)-3-(3,4-difluorophenyl)-5-oxomorpholine-4-carboxylic acid 3-[4-(5-fluoro-2-methoxyphenyl)-4-phenylpiperidin-1-yl]propylamide. The latter bound to human α1a receptors with Ki = 1.6 nM.

IT **277295-67-7P 277295-79-1P 277295-81-5P**
277296-20-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of morpholine derivs. as selective antagonists of α1a receptors)

RN 277295-67-7 CAPLUS
CN 4-Morpholinecarboxamide, 3-(3,4-difluorophenyl)-N-[3-[4-(5-fluoro-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-5-oxo-, monohydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 277295-79-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[3-[4-(5-fluoro-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-3-oxo-5-phenyl-, monohydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 277295-81-5 CAPLUS
CN 4-Morpholinecarboxamide, 3-(3,4-difluorophenyl)-N-[3-[4-(5-fluoro-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-2-methyl-5-oxo-, monohydrochloride, (2R,3R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



● HCl

RN 277296-20-5 CAPLUS
CN 4-Morpholinecarboxamide, 3-(3,4-difluorophenyl)-N-[3-[4-(5-fluoro-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-5-oxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **277295-95-1P 277296-11-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of morpholine derivs. as selective antagonists of α1a receptors)
RN 277295-95-1 CAPLUS
CN 1-Piperidinepropanamine, 4-(5-fluoro-2-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 277296-11-4 CAPLUS
CN Carbamic acid, [3-[4-(5-fluoro-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1999:662323 CAPLUS
DOCUMENT NUMBER:	132:44482
TITLE:	Design and synthesis of novel dihydropyridine alpha-1A antagonists
AUTHOR(S):	Marzabadi, Mohammad R.; Hong, Xingfang; Nagarathnam, Dhanapalan; Miao, ShouWu; Chiu, George; Wong, Wai C.; Wetzel, John M.; Fang, James; Forray, Carlos; Chen, Tsing B.; O'Malley, Stacey S.; Chang, Raymond S. L.; Gluchowski, Charles
CORPORATE SOURCE:	Department of Chemistry, Synaptic Pharmaceutical Corporation, Paramus, NJ, 07652, USA
SOURCE:	Bioorganic & Medicinal Chemistry Letters (1999), 9(19), 2843-2848 CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER:	Elsevier Science Ltd.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB A series of analogs of SNAP 5150 containing heteroatoms at C2 or C6 positions is described. Herein, the authors report that the presence of alkyl substituted heteroatoms at the C2(6)-positions of the dihydropyridine are well tolerated. In addition, SNAP 5399 inhibited the phenylephrine induced contraction of dog prostate tissue with a Kb of 1.5 nM and showed a Kb (DBP, dogs, μg/kg)/Kb (IUP, dogs, μg/kg) ratio of 14.8/2.5.

IT **166808-19-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(design and synthesis of novel dihydropyridine alpha-1A antagonists in relation to structure and inhibition of prostate contraction and bioavailability)
RN 166808-19-1 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-N3-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-6-methyl-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1999:9823 CAPLUS
DOCUMENT NUMBER:	130:81508
TITLE:	Heterocyclic substituted oxazolidinones for use as selective antagonists for human α1A receptors
INVENTOR(S):	Lagu, Bharat; Dhar, T. G. Murali; Nagarathnam, Dhanapalan; Jeon, Yoon T.; Marzabadi, Mohammad R.; Wong, Wai C.; Gluchowski, Charles; Tian, Dake
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corporation, USA
SOURCE:	PCT Int. Appl., 258 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857940	A1	19981223	WO 1998-US12668	19980617
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2294549	AA	19981223	CA 1998-2294549	19980617
AU 9881498	A1	19990104	AU 1998-81498	19980617
AU 740064	B2	20011025		
EP 988295	A1	20000329	EP 1998-931350	19980617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002505683	T2	20020219	JP 1999-504778	19980617
PRIORITY APPLN. INFO.:			US 1997-877846	A 19970618
			WO 1998-US12668	W 19980617

OTHER SOURCE(S): MARPAT 130:81508
GI



I

AB This invention is directed to oxazolidinone compds. which are selective antagonists for human α1A receptors. These compds. lower intraocular pressure, inhibit cholesterol synthesis, relax lower urinary tract tissue, and are useful in the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia etc. Thus, 4-(3,4-difluorophenyl)oxazolidinone was treated with 1,5-dibromopentane,

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
followed by 1-(2-methoxyphenyl)piperazine to give the oxazolidinone I which had a binding affinity for human α1A receptors of 0.5 nM.

IT **218449-44-6P 218449-45-7P 218451-03-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic substituted oxazolidinones for use as selective
antagonists for human α1A receptors)

RN 218449-44-6 CAPLUS
CN Carbamic acid, [3-[4-(5-bromo-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 218449-45-7 CAPLUS
CN 1-Piperidinepropanamine, 4-(5-bromo-2-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 218451-03-7 CAPLUS
CN 1-Imidazolidinecarboxamide, 5-(3,4-difluorophenyl)-N-[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]-2-oxo-3-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **218449-46-8P 218451-05-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic substituted oxazolidinones for use as selective
antagonists for human α1A receptors)

RN 218449-46-8 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[3-[4-(5-bromo-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-4-(3,4-difluorophenyl)-2-oxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 218451-05-9 CAPLUS
CN 1-Imidazolidinecarboxamide, 5-(3,4-difluorophenyl)-N-[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **218449-47-9P 218451-09-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic substituted oxazolidinones for use as selective
antagonists for human α1A receptors)

RN 218449-47-9 CAPLUS
CN 3-Oxazolidinecarboxamide, N-[3-[4-(5-bromo-2-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-4-(3,4-difluorophenyl)-2-oxo-, monohydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 218451-09-3 CAPLUS
CN 1-Imidazolidinecarboxamide, 5-(3,4-difluorophenyl)-N-[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:764290 CAPLUS
DOCUMENT NUMBER: 130:25077
TITLE: Preparation of piperidinylpropylaminocarbonyldihydropyrimidones and related compounds as selective adrenergic α1A receptor antagonists.
INVENTOR(S): Wong, Wai C.; Lagu, Bharat; Nagarathnam, Dhanapalan; Marzabadi, Mohammad R.; Gluchowski, Charles
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA
SOURCE: PCT Int. Appl., 314 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9851311	A2	19981119	WO 1998-US10082		19980515
WO 9851311	A3	19990114			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
US 6245773	B1	20010612	US 1997-858017		19970516
AU 9876872	A1	19981208	AU 1998-76872		19980515
US 2002010186	A1	20020124	US 2001-855597		20010515
PRIORITY APPLN. INFO.:			US 1997-858017	A	19970516
			US 1996-17801P	P	19960516
			WO 1998-US10082	W	19980515

OTHER SOURCE(S): MARPAT 130:25077
GI



AB Title compds. [I, II, III; A = specified (substituted) (hetero)aryl; X = S, O, NR3; R1 = H, NO2, cyano, alkyl, fluoroalkyl, alkenyl, alkynyl, cycloalkyl, fluorocycloalkyl, cycloalkenyl, N(R3)2, OR3, COR3, CO2R3, CON(R3)2; R2 = H, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, fluoroalkyl, alkenyl, alkynyl, cycloalkyl, fluorocycloalkyl, cycloalkenyl, cycloalkylalkyl, cyano, OR3, etc.; R3 = H, alkyl, fluoroalkyl, alkenyl, alkynyl, cycloalkyl, fluorocycloalkyl, cycloalkenyl; R4 = specified substituted heterocyclylpiperidinylalkyl, etc.; n = 0-5], were prepared I are useful for lowering intraocular pressure, inhibiting cholesterol

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

synthesis, relaxing lower urinary tract tissue, treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, etc. Thus, (+)-5-carboxamido-4-ethyl-1-{N-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)propyl]}carboxamido-6-(4-nitrophenyl)-2-oxo-1,2,3,6-tetrahydropyrimidine (prepn. given) bound to human α1A receptors with pKi = 9.74.

IT **200050-42-6P 200050-45-9P 200051-01-0P**
200051-57-6P 216310-39-3P 216311-38-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinylpropylaminocarbonyldihydropyrimidones as selective adrenergic α1A receptor antagonists)

RN 200050-42-6 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-1-[[[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-6-(4-nitrophenyl)-2-thioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 200050-45-9 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-1-[[[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 200051-01-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-1-[[[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-2-oxo-, methyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 200051-57-6 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-1-[[[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-2-oxo-, methyl ester, monohydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 216310-39-3 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-1-[[[3-[4-(4-hydroxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-2-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 216311-38-5 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-1-[[[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT **166809-56-9P 216311-08-9P 216311-32-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidinylpropylaminocarbonyldihydropyrimidones as selective adrenergic α1A receptor antagonists)

RN 166809-56-9 CAPLUS
CN 1-Piperidinepropanamine, 4-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 216311-08-9 CAPLUS
CN 1-Piperidinepropanamine, 4-(2-methoxy-5-methylphenyl)-4-phenyl- (9CI) (CA

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



RN 216311-32-9 CAPLUS
CN Carbamic acid, [3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:414735 CAPLUS
DOCUMENT NUMBER: 129:67709
TITLE: Dihydropyridine derivatives for treatment of benign prostatic hyperplasia
INVENTOR(S): Gluchowski, Charles; Wetzel, John M.; Chiu, George; Marzabadi, Mohammed R.; Wong, Wai C.; Nagarathnam, Dhanapalan
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA
SOURCE: U.S., 160 pp., Cont.-in-part of U.S. Ser. No. 166,367, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5767131	A	19980616	US 1996-211764	19960223
WO 9422829	A2	19941013	WO 1994-US3852	19940405
WO 9422829	A3	19950105		
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9402360	A	19950522	ZA 1994-2360	19940405
US 6211198	B1	20010403	US 1998-98699	19980615
US 6310076	B1	20011030	US 2000-588973	20000607
US 2002193599	A1	20021219	US 2001-972801	20011005
US 6608086	B2	20030819		

PRIORITY APPLN. INFO.:

US 1993-43212	B2 19930405
US 1993-120169	B2 19930910
US 1993-166367	B2 19931210
WO 1994-US3852	W 19940405
US 1993-166308	A 19931210
US 1996-211764	A3 19960223
US 1998-98699	A3 19980615
US 2000-588973	A3 20000607

OTHER SOURCE(S): MARPAT 129:67709
GI

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

II



III

AB The dihydropyridine derivs. [I; R1 = linear or branched alkyl, alkoxyalkyl, aralkyl; R2, R4 = H, linear or branched alkyl; R3 = H, linear or branched alkyl, alkoxyalkyl, acyl; R5, R6 = H, OH, Cl, Br, F, NO2, CF3, cyano, NH2, etc.; R7, R8 = H, cyano, CF3, OH, alkoxy, etc.; Y = C1-5 alkylene, C4-8 alkylene interrupted by O, alkenylene, alkynylene, etc.; Z = O, NH, CH2], useful in treating benign prostatic hyperplasia, inhibition of cholesterol synthesis, and reduction in intraocular pressure, are prepared and formulated. Amidation of carboxylic acid II (preparation given) with 3-(4,4-diphenylpiperidino)propylamine in refluxing CH2Cl2 gave 50.8% title compound (±)-III, which showed Ki of 1.9 nmol/kg.in reducing urethral pressure in vivo in dogs.

IT **166807-19-8P 166807-35-8P 166807-43-8P 166807-47-2P 166808-17-9P 166808-19-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydropyridine derivs. as drugs)

RN 166807-19-8 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2-ethyl-1,4-dihydro-N3-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-6-methyl-4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 166807-35-8 CAPLUS
CN 3,5-Pyridinedicarboxamide, 1,4-dihydro-N-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-2,6-dimethyl-4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 166807-43-8 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2,6-diethyl-1,4-dihydro-N-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-N'-methyl-4-(4-nitrophenyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 166807-47-2 CAPLUS
CN 3,5-Pyridinedicarboxamide, N,2,6-triethyl-1,4-dihydro-N'-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 166808-17-9 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2-[(2-azidoethoxy)methyl]-1,4-dihydro-N3-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-6-methyl-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 166808-19-1 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-N3-[3-[4-

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-6-methyl-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 166809-56-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydropyridine derivs. as drugs)
RN 166809-56-9 CAPLUS
CN 1-Piperidinepropanamine, 4-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:752840 CAPLUS
DOCUMENT NUMBER: 128:61520
TITLE: Preparation of dihydropyrimidine derivatives as selective antagonists for human α1A-adrenergic receptors.
INVENTOR(S): Wong, Wai C.; Lagu, Bharat; Nagarathnam, Dhanapalan; Marzabadi, Mohammad R.; Gluchowski, Charles
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA
SOURCE: PCT Int. Appl., 271 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742956	A1	19971120	WO 1997-US8335	19970516
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253862	AA	19971120	CA 1997-2253862	19970516
AU 9730082	A1	19971205	AU 1997-30082	19970516
AU 727972	B2	20010104		
JP 2000506904	T2	20000606	JP 1997-541146	19970516
EP 1021185	A1	20000726	EP 1997-924745	19970516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 2002010186	A1	20020124	US 2001-855597	20010515

PRIORITY APPLN. INFO.:
US 1996-17801P P 19960516
US 1996-648768 A 19960516
US 1997-858017 A1 19970516
WO 1997-US8335 W 19970516

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I, II, and III; A = (un)substituted Ph, pyridyl, 1H-imidazolyl, or 1-imidazolyl, etc.; X = H, NO2, cyano, linear or branched C1-7 alkyl, mono- or polyfluoroalkyl, linear or branched C2-7 alkenyl or alkynyl, C3-7 cycloalkyl, mono- or polyfluorocycloalkyl, N(R3)2, OR3, (CH2)pOR3, COR3, CO2R3, CO(R3)2; R2 = H, linear or branched C1-7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, mono- or polyfluorocycloalkyl, linear or branched C2-7 alkenyl or alkynyl, C3-7 cycloalkyl or mono- or polyfluorocycloalkyl or cycloalkenyl, C3-10 cycloalkyl-C1-10 alkyl, C3-10 cycloalkyl-C1-10 mono- or polyfluorocycloalkyl, cyano, CH2XR3, CH2X(CH2)pNHR3, (CH2)n NHR3, CH2X(CH2)pN(R3)2, CH2X(CH2)pN3, OR3, etc.; p = 1-7; n = 0-5; R3 = H, linear or branched C1-7 alkyl, mono- or polyfluorocycloalkyl, linear or branched C2-7 alkyl or alkynyl, C3-7 cycloalkyl or mono- or polyfluorocycloalkyl or cycloalkenyl; R4 = Q; wherein Z1 = (CH2)o, CO (CH2)oCO, CO(CH2)o; m = 0-3; n = 1-3; V = O, S, CR5R7, C(R7)2, NR7; R = H,

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
F, linear or branched C1-7 alkyl, mono- or polyfluoroalkyl, linear or branched alkyl C2-7 alkenyl or alkynyl, N(R3)2, NO2, etc.; R5, R7 = H, F, Cl, Br, iodo, COR3, CO2R3, CON(R3)2, cyano, NO2, N(R3)2, OR3, SR3, (CH2)pOR3, (CH2)pSR3, etc.; R6 = H, linear or branched C1-7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, mono- or polyfluoroalkyl, C3-7 cycloalkyl]. This invention is also related to uses of these compds. for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where the antagonism of the α1A receptor may be useful. The invention further provides a pharmaceutical compn. comprising a therapeutically effective amt. of the above-defined compds. and a pharmaceutically acceptable carrier. Thus, a mixt. of 1-(5-chloropentyl)-6-(3,4-difluorophenyl)-1,6-dihydro-2,4-dimethyl-5-methoxycarbonylpyrimidine (prepn. given), 4-methoxycarbonyl-4-phenylpiperidine, K2CO3, and NaI, and 1,4-dioxane was refluxed overnight to give IV. IV in vitro showed binding affinities at cloned human α1d, α1b, and α1a receptors with pKi values of 6.17, 6.32, and 8.99, resp.
IT 200050-42-6P 200050-45-9P 200050-81-3P
200051-01-0P 200051-57-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydropyrimidine derivs. as selective antagonists for human
α1A-adrenergic receptors for disease treatment)
RN 200050-42-6 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-1-[[[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-6-(4-nitrophenyl)-2-thioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 200050-45-9 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-1-[[[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 200050-81-3 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-1-[[[3-[4-(4-hydroxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-2-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200051-01-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-1-[[[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-2-oxo-, methyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 200051-57-6 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-1-[[[3-[4-(2-methoxy-5-methylphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-2-oxo-, methyl ester, monohydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 200052-35-3 CAPLUS
CN Carbamic acid, [3-[4-(5-methoxy-2-methylphenyl)-4-phenyl-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

IT 166809-56-9P 200052-34-2P 200052-35-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydropyrimidine derivs. as selective antagonists for human
α1A-adrenergic receptors for disease treatment)
RN 166809-56-9 CAPLUS
CN 1-Piperidinepropanamine, 4-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 200052-34-2 CAPLUS
CN 1-Piperidinepropanamine, 4-(5-methoxy-2-methylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:473181 CAPLUS
DOCUMENT NUMBER: 125:142759
TITLE: Preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α1c antagonists
INVENTOR(S): Nagarathnam, Dhanapalan; Chiu, George; Dhar, T. G. Murali; Wong, Wai C.; Marzabadi, Mohammad R.; Gluchowski, Charles; Lagu, Bharat; Miao, Shou Wu
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA
SOURCE: PCT Int. Appl., 229 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9614846	A1	19960523	WO 1995-US15025	19951116
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2205384	AA	19960523	CA 1995-2205384	19951116
CA 2205384	C	20040629		
AU 9642398	A1	19960606	AU 1996-42398	19951116
AU 714640	B2	20000106		
EP 790826	A1	19970827	EP 1995-940748	19951116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1173132	A	19980211	CN 1995-197348	19951116
JP 10510247	T2	19981006	JP 1996-516354	19951116
JP 3200070	B2	20010820		
BR 9509700	A	19981103	BR 1995-9700	19951116
HU 77941	A2	19981228	HU 1998-1222	19951116
CA 2237774	AA	19970522	CA 1996-2237774	19961115
WO 9717969	A1	19970522	WO 1996-US18573	19961115
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9710558	A1	19970605	AU 1997-10558	19961115
AU 714287	B2	19991223		
ZA 9609612	A	19970721	ZA 1996-9612	19961115
EP 866708	A1	19980930	EP 1996-941406	19961115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000500470	T2	20000118	JP 1997-519157	19961115
NO 9702236	A	19970701	NO 1997-2236	19970515
FI 9702087	A	19970714	FI 1997-2087	19970515
US 6268369	B1	20010731	US 1997-836628	19970516
US 5942517	A	19990824	US 1997-978682	19971126
US 6228861	B1	20010508	US 1998-68782	19981110
US 6248747	B1	20010619	US 1999-291553	19990414

L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 6727257	B1	20040427	US 2000-730458		20001205
PRIORITY APPLN. INFO.:			US 1994-340611	A	19941116
			WO 1995-US15025	W	19951116
			US 1996-648770	A	19960516
			WO 1996-US18573	W	19961115
			US 1997-836628	A1	19970516
			US 1997-978682	A3	19971126

OTHER SOURCE(S): MARPAT 125:142759
GI



I



II

AB Title compds. [e.g., I; R = (un)substituted (hetero)aryl; R1 = H, (fluoro)alkyl, cyano, ,CO2R3, etc.; R2 = H, alkyl, OR3, etc.; R3 = H, (fluoro)alkyl, etc.; R4 = e.g, (4-arylpiperidinopropyl)carbamoyl; X = O, S, (alkyl)imino] were prepared Thus, title compound II had pKi of 9.74 for binding at human α1c receptors in vitro.

IT **179480-91-2P 179480-95-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α1c antagonists)

RN 179480-91-2 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-1-[[[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-6-(4-nitrophenyl)-2-thioxo-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 179480-95-6 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-1-[[[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT **166809-56-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α1c antagonists)

RN 166809-56-9 CAPLUS
CN 1-Piperidinepropanamine, 4-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1995:750506 CAPLUS
DOCUMENT NUMBER:	123:143638
TITLE:	preparation of dihydropyridine derivatives as drugs
INVENTOR(S):	Gluchowski, Charles; Wetzel, John M.; Chiu, George; Marzabadi, Mohammad R.; Wong, Wai C.; Nagarathnam, Dhanapalan
PATENT ASSIGNEE(S):	Synaptic Pharmaceutical Corp., USA
SOURCE:	PCT Int. Appl., 760 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422829	A2	19941013	WO 1994-US3852	19940405
WO 9422829	A3	19950105		
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9464986	A1	19941024	AU 1994-64986	19940405
ZA 9402360	A	19950522	ZA 1994-2360	19940405
US 5767131	A	19980616	US 1996-211764	19960223
US 6211198	B1	20010403	US 1998-98699	19980615
US 6310076	B1	20011030	US 2000-588973	20000607
US 2002193599	A1	20021219	US 2001-972801	20011005
US 6608086	B2	20030819		

PRIORITY APPLN. INFO.:	US 1993-43212	A	19930405
	US 1993-120169	A	19930910
	US 1993-166308	A	19931210
	US 1993-166367	B2	19931210
	WO 1994-US3852	W	19940405
	US 1996-211764	A3	19960223
	US 1998-98699	A3	19980615
	US 2000-588973	A3	20000607

OTHER SOURCE(S): MARPAT 123:143638
GI

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I II



III

AB Dihydropyridine derivs. [I; R1 = linear or branched alkyl, alkoxyalkyl, aralkyl; R2, R4 = H, linear or branched alkyl; R3 = H, linear or branched alkyl, alkoxyalkyl, acyl; R5, R6 = H, OH, Cl Br, F, NO2 CF3, cyano, NH2, etc.; R7, R8 = H, cyano, CF3, OH, alkoxy, etc.; Y = C1-5 alkylene, C4-8 alkylene interrupted by O, alkenylene, alkynylene, etc.; Z = O, NH, CH2], useful in treating benign prostatic hyperplasia, inhibition of cholesterol synthesis, and reduction in intraocular pressure, are prepared and formulated.
Amidation of carboxylic acid II (preparation given) with 3-(4,4-diphenylpiperidino)propylamine in refluxing CH2Cl2 gave 58.8% title compound (±)-III, which showed Ki of 1.9 nmol/kg in reducing urethral pressure in vivo in dogs.

IT **166807-19-8P 166807-35-8P 166807-43-8P**
166807-47-2P 166808-17-9P 166808-19-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydropyridine derivs. as drugs)

RN 166807-19-8 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2-ethyl-1,4-dihydro-N3-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-6-methyl-4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 166807-35-8 CAPLUS
CN 3,5-Pyridinedicarboxamide, 1,4-dihydro-N-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-2,6-dimethyl-4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 166807-43-8 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2,6-diethyl-1,4-dihydro-N-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-N'-methyl-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-6-methyl-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 166809-56-9
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydropyridine derivs. as drugs)

RN 166809-56-9 CAPLUS
CN 1-Piperidinepropanamine, 4-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 166807-47-2 CAPLUS
CN 3,5-Pyridinedicarboxamide, N,2,6-triethyl-1,4-dihydro-N'-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 166808-17-9 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2-[(2-azidoethoxy)methyl]-1,4-dihydro-N3-[3-[4-(4-methoxyphenyl)-4-phenyl-1-piperidinyl]propyl]-6-methyl-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 166808-19-1 CAPLUS
CN 3,5-Pyridinedicarboxamide, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-N3-[3-[4-

L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1992:33860 CAPLUS
DOCUMENT NUMBER:	116:33860
TITLE:	The metabolic fate of the antiparkinsonian drug budipine in rats
AUTHOR(S):	Caputo, O.; Grosa, G.; Ceruti, M.; Rocco, F.; Biglino, G.
CORPORATE SOURCE:	Ist. Chim. Farm. Appl., Univ. Torino, Turin, I-10125, Italy
SOURCE:	European Journal of Drug Metabolism and Pharmacokinetics (1991), 16(2), 113-18 CODEN: EJDPD2; ISSN: 0398-7639
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB The metabolic fate of the antiparkinsonian drug budipine was studied in rats after oral administration. The presence of an aromatic hydroxylation product, metabolite M1, and its O-sulfate conjugate was confirmed. Three new minor metabolites, budipine N-oxide, metabolite M1 N-oxide, and a secondary metabolite derived from M1 via hydroxylation of a Me of the tert-Bu group, were identified in urine. The presence of a metabolite, M1-glucuronic acid conjugate, was also established using different enzymic treatments of urine.

IT 138306-43-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmacokinetics of, as budipine metabolite)

RN 138306-43-1 CAPLUS
CN 1-Piperidineethanol, 4-(4-hydroxyphenyl)-β,β-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)